Citius Pharmaceuticals (FRA:47N0) 3-Year EBITDA Growth Rate : 18.40% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals 3-Year EBITDA Growth Rate?

Citius Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2024 was €-1.41.

During the past 3 years, the average EBITDA Per Share Growth Rate was 18.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Citius Pharmaceuticals was 43.50% per year. The lowest was -294.20% per year. And the median was 24.40% per year.

Competitive Comparison of Citius Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Citius Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Citius Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Citius Pharmaceuticals (FRA:47N0) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Citius Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (FRA:47N0) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CTXR:USA

Address

11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016

Website

https://www.citiuspharma.com

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Citius Pharmaceuticals Headlines

No Headlines